ArticleBJU international2025
Pelvic organ-sparing robot-assisted radical cystectomy in women with bladder cancer.
Article in BJU international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Management of surgical menopause in female patients with bladder cancer undergoing radical cystectomy.Nature reviews. Urology · 2026Review
- How to Minimize Hyper-Continence After Intracorporeal Robotic Neobladder Configuration in Women? The Three-Layer Posterior Reconstruction During Florence Robotic IntraCorporeal Neobladder (FloRIN).Journal of clinical medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo investigate the oncological and complication outcomes in women who have undergone pelvic organ-sparing robot-assisted radical cystectomy (RARC). PATIENTS AND
methodsWe conducted a retrospective, multicentre cohort study of women with bladder cancer undergoing RARC with intracorporeal urinary diversion. The primary outcomes were overall survival (OS) and cancer-specific survival (CSS), and secondary outcomes were 30- and 90-day high-grade complications in patients undergoing organ-sparing RARC vs non-organ-sparing RARC. Kaplan-Meier analyses, the log-rank test and Cox proportional hazard models were used to assess the associations of pelvic organ-sparing RARC with both OS and CSS. The Mann-Whitney test and chi-squared and Fisher's tests were used to compare continuous and categorical variables, respectively.
resultsA total of 269 women underwent RARC, of whom 81 underwent pelvic organ-sparing RARC. There was no statistically significant difference between the groups in terms of clinical or pathological T stage, and the recurrence rates were similar in the two groups. There were no significant differences in CSS or OS between the groups. The two groups had similar complication profiles and rates. The incidence of high-grade (Clavien-Dindo grade ≥3a) complications was similar in the two groups: organ-sparing vs non-organ-sparing RARC: 13% vs 14% for early complications (P = 0.87) and 7% vs 6% (P = 0.70) for late complications.
conclusionsWomen with bladder cancer who underwent pelvic organ-sparing RARC and intracorporeal urinary diversion had similar oncological and complication outcomes compared to those who underwent non-organ-sparing RARC. Pelvic organ-sparing RARC could be considered in well selected women with bladder cancer, resulting in improved quality of life and functional outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.